AI - BE-Smart

“As we move forward with Project ZenQ-AI, our aim is to redefine the boundaries of precision oncology,” stated Ted Karkus, CEO of ProPhase Labs. “I believe our BE-Smart esophageal cancer test is groundbreaking in the diagnosis of esophageal cancer. And now we are already evolving with our AI platform that leverages our esophageal cancer diagnostics proprietary knowledge with our vast genomic database. Our AI initiative represents our commitment to transforming patient outcomes with significantly more targeted and effective cancer therapies.”

ProPhase Labs is a next- generation biotech, genomics and diagnostics company focused on creating a healthier world through bold action and the power of insight. Find us on the Nasdaq, stock symbol PRPH.

We dream big and execute smartly through our diversified subsidiaries.


Introducing Project ZenQ-AI: Revolutionizing Cancer Treatment with AI and Genomics

ProPhase Labs, Inc., a leader in biopharma, genomics, and diagnostics, is proud to announce an innovative leap in cancer treatment research with the launch of Project ZenQ-AI. This cutting-edge initiative combines advanced artificial intelligence with an extensive genomics database to pioneer the development of antibody drug conjugates (ADCs) for more effective cancer treatments.

The Power of Artificial Intelligence in Medicine

“Project ZenQ-AI doesn’t just utilize state-of-the-art AI technology; it’s differentiated by the unparalleled genomic database we’ve curated,” explains Sergio Miralles, CIO at ProPhase Labs. “This fusion of sophisticated AI and rich, diverse data ensures our approach to cancer treatment is both revolutionary and precise.”

What Are Antibody Drug Conjugates (ADCs)?

ADCs represent a novel class of cancer therapies that differ from traditional treatments. They specifically target cancer cells, minimizing damage to healthy tissues. ADCs link chemotherapy agents to monoclonal antibodies, which bind selectively to markers on cancer cells, delivering potent drugs directly to the tumor while sparing normal cells.

Leveraging Genomics and Technology

Project ZenQ-AI harnesses:

– Whole Genome Sequencing (WGS): Analyzing all 3 billion base pairs of the human genome to explore genetic factors influencing diseases and treatment responses.

– Advanced AI and Machine Learning: Utilizing both cloud-based AI platforms and on-premise NVIDIA GPUs to process and analyze vast amounts of genomic data efficiently and securely.

Global Impact and Future Prospects

With contributions from over 130 countries, Project ZenQ-AI’s genomic database is uniquely positioned to identify genetic markers and therapeutic targets across diverse populations, enhancing the universality and effectiveness of ADC treatments.

“We stand on the brink of transforming cancer treatment through the power of AI and genomic insights,” says Ted Karkus, CEO of ProPhase Labs. “Our AI initiative represents our commitment to transforming patient outcomes with significantly more targeted and effective cancer therapies.”

Dev Tool:

Request: ai-be-smart
Matched Rewrite Rule: (.?.+?)(?:/([0-9]+))?/?$
Matched Rewrite Query: pagename=ai-be-smart&page=
Loaded Template: page.php